Harpreet Singh, Chief Medical Officer of Precision for Medicine, shared a post on LinkedIn:
“ADCs continue to reshape oncology, not just as late-line options but as contenders for frontline treatment across solid tumors and hematologic malignancies.
In our new white paper, ‘Advancing ADCs to the Frontline Setting,’ Nicholas Richardson and I explore case studies that show how successful programs have navigated that transition and how thoughtful trial design, toxicity management, and smart combination strategies create real pathway-changing opportunities.
The paper also outlines the operational and regulatory considerations teams should be thinking about now if they want their ADC to reach broader patient populations.
If you’re developing an ADC and looking to advance it toward the frontline setting, read our latest white paper and reach out to continue the conversation with our team at Precision For Medicine.
Visit instituteatprecision.com to download the white paper today!”
Proceed to the video attached to the post.
More posts featuring Harpreet Singh.